Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 12/21/18
End: 11/01/20
Due: 11/01/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059) | NCT06982287 | Yong Fang | user2@example.com | None | 2025-06-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC | NCT03726736 | Yong Fang | user2@example.com | None | 2018-12-21 | 2020-11-01 | 2021-11-01 | - | - | 2025-07-14 |